...
首页> 外文期刊>Biomedical Sciences >Ebastine, a Mast Cell Blocker Improves Sperm Motility in Asthenospermic Infertile Men
【24h】

Ebastine, a Mast Cell Blocker Improves Sperm Motility in Asthenospermic Infertile Men

机译:Ebastine,肥大细胞阻断剂改善了哮喘患者不孕症男性的精子运动

获取原文
           

摘要

Introduction: The right treatment of male infertility is relatively costly procedure. So we should sincerer about the treatment procedure to evaluate the role of mast cell blocker ebastin in male infertility for the sake of the wellbeing of our people. The study aims to observe and evaluate the effect of Mast cell (MC) blocker Ebastin in the improvement of sperm motility in asthenospermic infertile male. Methods: This was a longitudinal clinical trial study and was conducted in the Infertility Unit outdoor, Department of obstetrics and gynecology, Bangabandhu Sheikh Mujib Medical University, Dhaka. Bangladesh during the period from January 2015 to December 2015. This study was conducted among the male patients and followed Purposive sampling technique. Finally, 334 cases were enrolled in this study. Among the male with abnormal semen parameter 168 patients were Asthenozospermic and 60 patients were combined Oligo-asthenozospermic. Statistical analysis was carried out by using the SPSS 16.0 & MS-Excel2016. Result: From 334 study people we found in group I, mean sperm total mortality was 24.8612.02% in pretreatment and 34.299.35% in post treatment. The difference was statistically significant (p0.05). In group II, mean sperm total mortality was 21.966.17% in pretreatment and 22.444.81% in post treatment. The difference was not statistically significant (p0.05). Improved sperm motility was 75.4% of asthenozospermic male in ebastin group and 19.3% in placebo group. Which was statistically significant (p0.05). In group I, mean rapid progress was found 11.817.76% in pretreatment group and 19.9911.31% in post treatment. The difference was statistically significant (p0.05). In group II, mean rapid progress was found 11.251.67% in pretreatment group and 11.41.59% in post treatment. The difference was not statistically significant (p0.05). Conclusion: that sperm motility and rapid progress had significantly improved after three months' treatment period with Ebastin than Placebo. Therefore, this study suggested that mast cell blocker ebastin can be helpful than placebo to improve the patients' sperm motility with asthenozoospermia.
机译:简介:男性不孕症的正确治疗是相对昂贵的程序。因此,我们应该渴望治疗程序,以评估肥大细胞阻断剂EBASTIN在男性不孕症中的作用,以便我们人民的福祉。该研究旨在观察和评估肥大细胞(MC)阻断剂EBASTIN在哮喘患者不育雄性中精子运动的影响。方法:这是纵向临床试验研究,并在户外,户外,厄卡湖北部医科大学妇产科妇产科户外,达卡。孟加拉国在2015年1月至2015年12月期间。该研究进行了雄性患者并跟随有目的采样技术。最后,本研究报名参加334例。在具有异常精液参数168患者的男性中,哮喘患者,60名患者组合寡核苷酸。通过使用SPSS 16.0和MS-Excel2016进行统计分析。结果:从334名研究人群中发现,预处理的预处理总死亡率为24.8612.02%,治疗后34.299.35%。差异是统计学上显着的(P <0.05)。 II族中,预处理的平均性能总死亡率为21.966.17%,后治疗中的22.44.81%。差异在统计学上没有统计学意义(P& 0.05)。改善的精子活力为Ebastin组的75.4%的哮喘雄性,19.3%在安慰剂组中。统计学意义(P <0.05)。在第I群中,预处理组的意味着11.817.76%,后治疗中的预处理组和19.9911.31%。差异是统计学上显着的(P <0.05)。在II组中,预处理组的意味着11.251.67%,后治疗中11.41.59%。差异在统计学上没有统计学意义(P& 0.05)。结论:在eBastin的三个月治疗期后,精子的运动和快速进展明显改善了Ebastin的Puldbo。因此,本研究表明,肥大细胞阻断剂EBASTIN可能比安慰剂有助于改善患者与哮喘患者的精子活力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号